Dr. Benjamin R. Tan, MD
Medical Oncology (Medical Oncology Physician)
4921 Parkview Pl, Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 321
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 105968
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
- Christian Hospital Northeast Saint Louis, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 321
- Services billed
- 59,612
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 21,040 | 20 |
| Injection, fosaprepitant, 1 mg | 17,250 | 46 |
| Injection, oxaliplatin, 0.5 mg | 11,600 | 18 |
| Injection, ferric carboxymaltose, 1 mg | 9,000 | 11 |
| Injection, pembrolizumab, 1 mg | 9,000 | 22 |
| Injection, azacitidine, 1 mg | 5,900 | 12 |
| Injection, denosumab, 1 mg | 4,740 | 33 |
| Injection, docetaxel, 1 mg | 3,258 | 18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,360 | 95 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1,430 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $373,594 in research payments for these studies, mostly to the institutions running them.
- Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - A phase 1 dose escalation and cohort expansion study of TSR-022, an an
GlaxoSmithKline, LLC. - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie Inc. - A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT06109272 - M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatoce…
AbbVie Inc. - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Car…
AbbVie Inc. - Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1
AstraZeneca Pharmaceuticals LP - A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Th…
Exelixis Inc. - A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation
E.r. Squibb & Sons, L.l.c. - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie Inc. · Recruiting · NCT06858813
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.